Company Overview of Alcobra Ltd.
Alcobra Ltd., a biopharmaceutical company, focuses on the development and commercialization of oral drug candidates. The company is primarily developing MDX (metadoxine), an onset/extended release formulation of the chemical pyridoxine pyroglutamate, which is in Phase III clinical trial for adults with attention deficit hyperactivity disorder (ADHD); in Phase II clinical trial for pediatric with ADHD; and in Phase II clinical trial in adolescents and adults with Fragile X Syndrome. Alcobra Ltd. was founded in 2008 and is headquartered in Tel Aviv, Israel.
Amot Investment Building
2 Weizman Street
Tel Aviv, 6423902
Founded in 2008
972 72 220 4661
Key Executives for Alcobra Ltd.
Alcobra Ltd. does not have any Key Executives recorded.
Alcobra Ltd. Key Developments
Similar Private Companies By Industry
|SimeTRA Pharm Ltd.||Middle East/Africa|
|Perrigo Israel Pharmaceuticals Limited||Middle East/Africa|
|Topimed Ltd.||Middle East/Africa|
|ConjuGate Ltd.||Middle East/Africa|
|Sol-Gel Technologies Ltd.||Middle East/Africa|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact Alcobra Ltd., please visit www.alcobra-pharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.